58 results about "Post-traumatic stress disorder (PTSD)" patented technology

Provided herein are substituted amphetamines, processes of preparation and pharmaceutical compositions thereof. Also provided are methods of their use for the treatment and / or management of trauma associated with a terminal disease, a post-traumatic-stress-disorder, or a psychological disorder.

Disclosed is a method of treating Psychotic Depression, Suicidal Ideation, Disruptive Mood Dysregulation Disorder, Persistent Depressive Disorder (Dysthymia), Premenstrual Dysphoric Disorder, Substance / Medication-Induced Depressive Disorder, Depressive Disorder Due to Another Medical Condition, Other Specified Depressive Disorder, Unspecified Depressive Disorder, Separation Anxiety Disorder, Selective Mutism, Specific Phobia, Social Anxiety Disorder (Social Phobia), Panic Disorder, Panic Attack (Specifier), Agoraphobia, Generalized Anxiety Disorder, Substance / Medication-Induced Anxiety Disorder, Anxiety Disorder Due to Another Medical, Other Specified Anxiety Disorder, Unspecified Anxiety Disorder, or fatigue, the method including administering a pharmaceutical composition containing an effective amount of an active agent, wherein the active agent is purified (2R,6R)-hydroxynorketamine, purified (2S,6S)-hydroxynorketamine, or a combination thereof, or a pharmaceutically acceptable saltthereof, together with a pharmaceutically acceptable carrier to a patient in need of such treatment.

The present invention provides compounds of formula I which are capable of inhibition of the activation of hNav1.1 or hNav1.6 sodium channels in neurons. Pharmaceutical compositions comprising these compounds are also provided. Methods for prevention and treatment of neurological disorders, including, for example, seizures and seizure disorders, including Lennox-Gastaut Syndrome, Dravet syndrome, epileptic encephalopathies, autism, Familial hemiplegic migraine (FHM), anxiety disorders, including Post-traumatic stress disorder (PTSD), panic disorder and obsessive-compulsive disorder, neuropathic pain, and Rett syndrome by administration of these compounds are also provided.

Provided are methods of treating post-traumatic stress disorder with rufinamide. Also provided are methods of treating kindling and improving resilience with rufinamide. Also provided are methods of diagnosing post-traumatic stress disorder in a patient by administering to the patient a therapeutically effective amount of rufinamide and assessing at least one of sign, symptom, or symptom cluster of post-traumatic stress disorder; and diagnosing post-traumatic stress disorder in the patient if the rufinamide reduces at least one of sign, symptom, and symptom cluster of post-traumatic stress disorder.

The present compounds compounds are oxytocin receptor agonists for the treatment of autism, stress, including post traumatic stress disorder, anxiety, including anxiety disorders and depression, schizophrenia, psychiatric disorders and memory loss, alcohol withdrawal, drug addiction and for the treatment of Prader-Willi Syndrome.

The invention discloses application of a small dose of propofol in preparing products for preventing and curing post-traumatic stress disorder (PTSD). Stress disorder and its related diseases include acute stress disorder (ASD) and PTSD. According to the test of injecting a small dose of propofol in the abdominal cavity of a PTSD pattern animal, the small dose of propofol has function of relieving fear, anxiety and learning and memory impairment of the PTSD pattern animal, and can decrease expressions of inducible nitric oxide synthase (iNOS) and neurons nitric oxide synthase (nNOS) which are caused by strong stress, increase expression of brain derived neurotrophic factor (BDNF) which plays an important role in neuroplasticity regulation and reduce release of nitric oxide (NO) of glioma cell of the pattern animal greatly. Accordingly, propofol with the advantages of quick action, quick metabolic clearance and no residues has good application prospect.

The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts or solvates thereof and pharmaceutically acceptable formulations comprising said compoundsuseful for the treatment of premature ejaculation, depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder, post-traumatic stress disorder and substance abuse disorders.

The invention relates to an application of a compound in resisting post-traumatic stress disorders, in particular to an application of a compound as shown in Formula I (shown as Description), or a tautomer, a racemate, an optical isomer or pharmaceutical salt of the compound in preparing a medicine for preventing or treating the post-traumatic stress disorders. The compound provided by the invention has a significant effect on the post-traumatic stress disorders, and the compound has the advantages of being rapid to take effects, free from sexual dysfunction and the like.

The invention provides an application of a polypeptide organic compound for interference in the function of an NMDA receptor in researches of learning and memory of mammals. The polypeptide organic compound is selected from A, B or C and can be used for effectively inhibiting an expression of a GluN2A-NMDA receptor induced by neuron activities, i.e., the polypeptide organic compound is a general mechanism affecting plasticity, so that the polypeptide organic compound can be applied to the preparation of therapeutic medicines for neuropsychological diseases relevant to the abnormal learning and memory mechanism. The polypeptide organic compound can perform effective interference in formation of conditioned fear memories, so that the polypeptide organic compound can be applied to the preparation of the therapeutic medicines relevant to post-traumatic stress disorder. The polypeptide organic compound can perform effective interference in the synaptic expression of the GluN2A-NMDA receptor induced by plasticity stimulus so as to affect learning and memory processes. The polypeptide organic compound is low in effective dose, cannot generate toxic and side effects on animals and has high specificity. As a result, the relevant researches can be carried out by utilizing the polypeptide organic compound to a maximum extent.

Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and / or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and / or premature ejaculation are described.

The invention provides a health management method for a post-traumatic stress disorder patient and a related device. The health management method comprises the following steps: acquiring health information of a user, performing user registration and establishing an electronic health record according to the acquired health information; displaying a selection box about the health management mode toenable a user to select a scene mode and a scene mode; receiving a selection result of the user for the health management mode, and determining the health management mode selected by the user; and displaying corresponding health management guidance suggestions according to the health management mode selected by the user. By adopting the health management method provided by the embodiment of the invention, long-term periodic management on the post-traumatic stress disorder patient can be assisted.

The present invention relates to a method of a) treating any of depression induced by chronic stress; depression in a subject afflicted with PTSD; anxiety induced by chronic stress; anxiety in a subject afflicted with PTSD; cognitive impairment induced by chronic stress; altered morphology and / or reduced number of GFAP+ cells in hippocampus and / or frontal cortex induced by chronic stress; working memory impairment in a subject afflicted with PTSD; b) inhibiting or reversing loss of GFAP+ cells in hippocampus and / or frontal cortex induced by chronic stress; c) decreasing consolidation of contextual fear memory in a subject afflicted with PTSD; d) enhancing extinction of fear memory in a subject afflicted with PTSD; or e) increasing calcineurin A expression in a subject afflicted with PTSD using a combination of cotinine and an antioxidant.

The present invention relates to compounds of general formula I wherein R1, R2, R3 and R4 are as defined herein which maybe used for the treatment of schizophrenia, obsessive-compulsivepersonality disorder, major depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, Parkinson's disease, dementia, Alzheimer's disease, cognitive impairment, chemotherapy-induced cognitive dysfunction (“chemobrain”), Down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, stroke, and disturbances due to radiation therapy, chronic stress, optic neuropathy or macular degeneration, or abuse of neuro-active drugs, selected from alcohol, opiates, methamphetamine, phencyclidine and cocaine.

The invention discloses an application of CBLB502 protein in prevention and treatment of post-traumatic stress disorder. The invention finds for the first time that CBLB502 can significantly inhibit symptoms of PTSD syndrome induced by electrical stimulation. The CBLB502 can be used for preventing and treating the PTSD. The invention is of great significance to the research of PTSD prevention andtreatment methods.

The present invention relates to novel dihydropyridine derivatives of formula (I): as modulators of nuclear receptors selected from androgen receptor and glucocorticoid receptor, to processes for their preparation, to pharmaceutical compositions comprising said compounds and to the use of said for manufacturing a medicament for the treatment of pathological conditions or diseases that can improveby modulation of androgen receptor and / or glucocorticoid receptor, selected from cancer, metastasizing cancers, benign prostate hyperplasia, polycystic ovary syndrome (PCOS), hair loss, hirsutism, acne, hypogonadism, muscle wasting diseases,cachexia, Cushing's syndrome, anti-psychotic drug induced weight gain, obesity, post-traumatic stress disorder and alcoholism.

The invention provides compounds of the Formula:that are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa, bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.

Disclosed herein are pharmaceutical compositions for the treatment of acquired brain injury (ABI), including traumatic brain injury (TBI) and acute non-traumatic brain injury (ANBI), post-traumatic stress disorder (PTSD), and other degenerative neurological disorders that may or may not be associated with ABI comprising an effective amount of one or more mTOR inhibitors and optionally an effective amount of one or more thyroid hormones. Further disclosed herein are methods of treating, preventing, reducing the intensity of or reducing the severity of ABI and / or PTSD, the method comprising administering an effective amount of one or more mTOR inhibitors and optionally an effective amount of one or more thyroid hormones.

Provided are compositions and methods for detecting and modulating oscillatory patterns within the basolateral amygdala (BLA) for diagnosis and treatment of anxiety related disorders.

The embodiment of the invention discloses a CBT(cognitive behavioral therapy)-based psychological therapy control method. The method comprises the following steps: acquiring a current learned psychological learning module of a user according to an unlocking instruction input by the user; obtaining the recent unlocking time of the learned psychological learning module, and judging whether the difference between the recent unlocking time and the current time is greater than or equal to a preset interval duration or not; if so, selecting one psychological learning module from unlearned psychological learning modules according to a preset learning sequence to serve as a psychological learning module to be learned; unlocking the psychological learning module to be learned, and displaying pathological explanation data and self-training data of the psychological learning module to be learned to the user in a man-machine conversation mode, wherein the psychological learning module is designedon the basis of the diagnosis standard and cognitive behavior therapy of the fifth-edition psychosis statistical diagnosis manual on the post-traumatic stress disorder. The method can help the user torelieve PTSD symptoms based on the cognitive behavior therapy.

The invention discloses a tetrandrine nasal preparation for treating post-traumatic stress disorder. Tetrandrine is prepared into temperature sensitive gel, a cubic liquid crystal and other nasal preparations, and the effect is good in treating the post-traumatic stress disorder through brain targeting.

The invention provides application of an uncaria active compound in preparation of a medicine for preventing and / or treating mental disorder diseases, and relates to the technical field of medical application. The mental disorder diseases comprise neurological and mental disorders caused by traumatic memory. The uncaria active compound disclosed by the invention can comprise rhynchophylline, isorhynchophylline, and derivatives, isomers and the like obtained by modifying molecular structures of the active compounds. The active compound provided by the invention can promote fading of wound memory, and has prevention and alleviation effects on neuropsychiatric disorders (such as post-traumatic stress disorder and phobia) and the like caused by the wound memory.

The present invention relates to novel dihydropyridine derivatives of formula (I):as modulators of nuclear receptors selected from androgen receptor and glucocorticoid receptor, to processes for their preparation, to pharmaceutical compositions comprising said compounds and to the use of said for manufacturing a medicament for the treatment of pathological conditions or diseases that can improve by modulation of androgen receptor and / or glucocorticoid receptor, selected from cancer, metastasizing cancers, benign prostate hyperplasia, polycystic ovary syndrome (PCOS), hair loss, hirsutism, acne, hypogonadism, muscle wasting diseases, cachexia, Cushing's syndrome, anti-psychotic drug induced weight gain, obesity, post-traumatic stress disorder and alcoholism.

Provided herein are methods for preventing or treating post-traumatic stress disorder (PTSD) in a subject, the methods including: administering an agent which inhibits formation of a glucocorticoid receptor (GR)-FK506 Binding Protein 51 (FKBP51) complex (GR-FKBP51 complex), or which disrupts already formed GR-FKBP51 complex, to the subject; thereby reducing a level of GR-FKBP51 complex in the subject and preventing or treating the PTSD. Also provided are methods for diagnosing a subject as having, or being at risk of developing, a PTSD, the methods including steps of: measuring a level of a GR-FKBP51 complex in the subject; comparing the measured level to a reference level of a non-PTSD condition; and identifying the subject as having, or being at risk of developing, PTSD where the measured level is elevated relative to the reference level. Agents, compositions, and / or kits for the diagnosis and / or treatment of PTSD are also described.